New CEO took over the reins
Jonathan M. Pratt has taken over as CEO of Qiagen N.V., succeeding Thierry Bernard who led the company for nearly seven years. Pratt brings over 25 years of international leadership experience in the life sciences and healthcare sectors, having previously served in senior roles at Filtration Group, Waters Corporation, and Beckman Coulter Life Sciences. Bernard will assist with the transition until the end of the year.
Danaher Corp. stock underperforms Friday when compared to competitors
Danaher Corp. (DHR) stock fell by 1.60% on Friday, closing at $207.66. This underperformance occurred during a generally negative trading session where the S&P 500 Index dropped 0.38% and the Dow Jones Industrial Average fell 0.51%. The decline ended a two-day winning streak for Danaher's stock.
Danaher Corp. stock trades near 52-week highs as investors digest recent earnings
Danaher Corp. (DHR) stock is trading near its 52-week highs, with shares opening at $210.69 on September 4, 2026, as investors evaluate its strong Q2 2026 financial results. The company reported mid-single-digit revenue growth and improved profitability, driven by efficiency programs and portfolio optimization. Danaher's defensive growth story, strong diagnostics and life-science tools portfolio, and optimistic full-year guidance contribute to its premium valuation.
Danaher (DHR) Seen Deftly Navigating AI Integration
Eagle Capital Management, in its Q2 2026 investor letter, highlighted Danaher Corporation (DHR) as a high-quality business with low volatility that is expected to skillfully integrate AI into its markets. The firm views Danaher, a healthcare and life science tools company, as having strong fundamentals despite market de-rating, predicting mid-teen EPS growth. While Eagle maintains selective exposure to AI beneficiaries, it suggests other AI stocks might offer greater upside and less downside risk.
Baird Adjusts Price Target on Danaher to $238 From $232, Keeps Outperform Rating
Baird has increased its price target on Danaher Corporation (DHR) to $238 from $232, while maintaining an "Outperform" rating on the stock. This adjustment reflects a positive outlook from the analyst firm regarding Danaher's future performance. Another firm, HSBC, also recently raised its price target on Danaher to $250 from $230, similarly maintaining a "Buy" rating.
Danaher (DHR) Stock Trades Near Fair Value But At An Earnings Premium
Danaher (DHR) stock, despite a 26.6% decline over five years, currently trades near its intrinsic value based on a Discounted Cash Flow (DCF) model but appears overvalued on traditional market multiples like the P/E ratio. The company received a low value score, indicating it leans expensive without a clear bargain. The article highlights that while DCF suggests it's 7.9% undervalued, its P/E of 37.0x is above its estimated fair P/E of 31.8x, posing a question for investors about justifying the premium.
Danaher (DHR) Stock Trades Near Fair Value But At An Earnings Premium
Danaher (DHR) stock has seen a 26.6% decline over the past five years, yet it now trades near its estimated intrinsic value based on a Discounted Cash Flow (DCF) model, suggesting it is slightly undervalued. However, the stock appears overvalued on traditional market multiples like the P/E ratio, trading at 37.0x against a fair estimate of 31.8x. This mixed valuation indicates that while the company's cash flow potential supports its current price, investors are paying a premium for its earnings compared to peers.
Danaher Corp. stock outperforms competitors on strong trading day
Danaher Corp. (DHR) shares rose 1.44% to $209.91 on Wednesday, outperforming the broader market. This gain broke a two-day losing streak for the stock. The S&P 500 Index and Dow Jones Industrial Average also saw gains during the trading session.
Danaher (NYSE:DHR): Is Its Valuation Hiding A Bigger Risk?
Danaher (NYSE:DHR) faces a valuation debate as its cash-flow analysis suggests the stock is reasonably aligned with intrinsic value, while earnings-based measures imply a richer valuation. The company, a major healthcare technology business, relies on diagnostics, innovation, and life sciences demand for growth, but a premium earnings multiple requires sustained operational strength. Future performance will depend on revenue trends, margin protection, new product adoption, and management execution to reconcile these differing valuation signals.
Empowered Funds LLC Makes New $3.58 Million Investment in Owens Corning Inc $OC
Empowered Funds LLC has initiated a new investment of $3.58 million in Owens Corning Inc (NYSE:OC) by acquiring 22,531 shares during the second quarter. This move aligns with significant institutional ownership in the company, which stands at 88.4%, and follows Owens Corning's strong quarterly earnings report that surpassed analyst expectations. Analysts maintain a "Moderate Buy" consensus rating for Owens Corning, with an average price target significantly above its recent trading price.
Danaher Corp Stock (DHR) Moved Down by 3.06% on Sep 1: Facts Behind the Movement
Danaher Corp (DHR) stock fell 3.06% on September 1, influenced by narrowed full-year core revenue growth projections, ongoing sector headwinds, and profit-taking. Executive leadership changes, including share sales by outgoing leadership, and scrutiny over the acquisition of Masimo also contributed to market caution and increased volatility. Despite better-than-expected quarterly net earnings, investor concerns persist regarding bioprocessing equipment shipment delays and the long-term implications of recent corporate actions.
Research Tools & Consumables Stocks Q2 Highlights: Bruker (NASDAQ:BRKR)
The article reviews the Q2 performance of several research tools and consumables stocks, highlighting Bruker (NASDAQ:BRKR) as having the weakest performance relative to analyst estimates and full-year guidance. In contrast, Avantor (NYSE:AVTR) achieved the best Q2 results with significant analyst estimate beats. Other companies like Waters Corporation (NYSE:WAT), Bio-Techne (NASDAQ:TECH), and Danaher (NYSE:DHR) also had varying Q2 outcomes.
HSBC Adjusts Price Target on Danaher to $250 From $230, Maintains Buy Rating
HSBC has increased its price target for Danaher Corporation (DHR) from $230 to $250, while reaffirming its "Buy" rating on the stock. Danaher Corporation is a diversified industrial and technology group, primarily focused on diagnostic, life sciences, and biotechnology equipment. The article notes recent news concerning Danaher, including CEO changes and previous analyst adjustments to its price target.
Is Charles River Laboratories International (CRL) Cheap After Its Medigen Vaccine Partnership?
Charles River Laboratories International (CRL) has drawn attention due to its recent partnership with Medigen Vaccine Biologics for next-generation vaccine work, utilizing its biologics testing and Next-Generation Sequencing platforms. While the company has seen a strong share price surge recently (64.91% in 90 days, 76.50% in 1 year), its 5-year return is down 35.88%. The most followed narrative values CRL at $313.61 per share, suggesting it is 8.1% undervalued compared to its recent close of $288.24, but investors are advised to consider risks including supply chain disruptions and its current net loss.
Whole Genome And Exome Sequencing Market Analysis Highlights Growth To $7.63 Billion By 2030 At 24.8% CAGR
The whole genome and exome sequencing market is projected to reach $7.63 billion by 2030, growing at a CAGR of 24.8%. This growth is fueled by technological advancements, increasing adoption in personalized medicine and diagnostics, and significant investments in sequencing infrastructure. Key players are focusing on ultra-fast NGS analysis to enhance speed and affordability, further driving market expansion.
Is Thermo Fisher Scientific Stock Outperforming the Nasdaq?
Thermo Fisher Scientific (TMO) has underperformed the Nasdaq Composite (NASX) year-to-date, falling 27.7% in the last three months compared to NASX's 1.9% fall, and its YTD gain of 7.4% lags NASX's 13.6% rise. However, over the past 52 weeks, TMO has outperformed the Nasdaq with a 27% gain against the index's 21.6% return, driven by recovering life-sciences demand and strong execution. Analysts maintain a "Strong Buy" rating for TMO, with a mean price target suggesting a 2.3% upside from current levels.
Danaher Corp. stock underperforms Monday when compared to competitors
Danaher Corp. (DHR) stock fell by 1.16% on Monday, closing at $213.56. This underperformance occurred on a day when the broader market also experienced declines, with the S&P 500 Index dropping 0.33% and the Dow Jones Industrial Average falling 0.70%. The stock's decline ended a two-day winning streak for Danaher.
Healthcare’s Best Week Since June Traces Back to a Single Moderna and Merck Cancer Trial
The healthcare sector experienced its strongest week since June, driven by positive late-stage clinical trial results for a tailored mRNA cancer treatment developed by Moderna and Merck. The trial demonstrated significant improvements in recurrence-free survival for melanoma patients, validating the effectiveness of personalized neoantigen vaccines. This success led to substantial stock surges for both companies and renewed enthusiasm across the biotech industry, though challenges remain regarding regulatory approval, commercial scalability, and the long-term revenue generation of personalized therapies.
QIAGEN Launches QIAsymphony Connect for Automated Nucleic Acid Extraction
QIAGEN has commercially launched QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction. This new system, building on the existing QIAsymphony, standardizes extraction across various assay workflows and supports applications like liquid biopsy. It features integrated liquid handling, prefilled IVD reagent cartridges, and automated load checks to enhance workflow automation, traceability, and process safety for high-throughput molecular testing.
Danaher Taps Diagnostics Executive Julie Sawyer Montgomery as CEO
Danaher has appointed Julie Sawyer Montgomery as its new President and Chief Executive Officer, effective October 1. Montgomery, who currently leads Danaher's Diagnostics platform, will succeed Rainer Blair, who is retiring. Her appointment follows a significant growth period for Danaher's Diagnostics business and recent acquisitions under her leadership.
Why Is Avantor (AVTR) Up 5.4% Since Last Earnings Report?
Avantor, Inc. (AVTR) shares have increased by 5.4% since its last earnings report, outperforming the S&P 500. The company reported better-than-expected Q2 2026 earnings due to growth in its VWR Distribution & Services segment, leading to raised full-year sales and EPS guidance. Despite a decline in its Bioscience & Medtech Products segment, analyst estimates for AVTR have been trending upward, earning it a Zacks Rank #2 (Buy).
Crane NXT Announces Appointment of Jason Lund as President of Crane Payment Innovations and Group President of the Detection and Traceability Technologies Segment
Crane NXT, Co. (NYSE: CXT) has appointed Jason Lund as President of Crane Payment Innovations (CPI) and Group President of its Detection and Traceability Technologies (DTT) segment. Mr. Lund will be responsible for driving growth, operational excellence, and customer-focused innovation within these segments. He brings over two decades of experience in operational excellence, mergers and acquisitions, and integration initiatives from previous roles at Novanta, Vontier, Fortive, and Danaher.
Orix JREIT Buying $185M Tokyo Office Stake, Taking Over Okinawa Complex
Orix JREIT is set to acquire a 50% stake in Tokyo's Toyosu Prime Square for $185 million and will fully acquire the Naha Shin-Toshin Center Building in Okinawa for JPY 10.6 billion. These acquisitions, totaling JPY 40 billion, are intended to enhance unitholder value by leveraging the properties' future upside potential. The transactions highlight a trend in Japanese REITs to rotate portfolios, with Orix JREIT and Daiwa House REIT both increasing their exposure to hospitality assets.
Danaher (DHR) Institutional Ownership 2026 $DHR
This article details the institutional ownership of Danaher (DHR) as of late August 2026, indicating that 79.05% of its stock is held by institutional investors. It lists major institutional buyers and sellers over the past 24 months, including California State Teachers Retirement System, Vanguard Group Inc., and BlackRock Inc. The report provides a granular view of recent institutional transactions, showing specific firms, shares held, market value, and quarterly changes in their holdings.
President Rainer Blair Sold A Bunch Of Shares In Danaher
Danaher Corporation's President, Rainer Blair, recently sold a significant portion of his shares, netting US$13 million and reducing his holding by 61%. This insider selling, along with a larger sale by Co-Founder Mitchell Rales for US$130 million, raises some caution, although the sales occurred near current prices. Despite the selling, insiders still own a substantial 11% of the company, valued at US$16 billion, and Danaher continues to be profitable and growing.
Insider Transaction: Rainer Blair Sells $12.74M Worth Of Danaher Shares
Rainer Blair, President & CEO of Danaher (NYSE: DHR), sold 58,255 shares of the company worth $12.74 million on August 24, as reported in an SEC Form 4 filing. The article also provides a detailed financial overview of Danaher, including its revenue trend, profitability metrics, debt management, and valuation ratios, noting its strong gross margin but lower EPS compared to industry averages. Danaher's shares were up 0.26% at $215.68 following the announcement.
Danaher Rides on Strength in Biotechnology Segment: Will It Sustain?
Danaher's Biotechnology segment continues to drive growth, with a 4% sales increase in Q2 2026, primarily due to strong demand in China and improved bioprocessing and medical businesses. Despite challenges like difficult prior-year comparisons in Western Europe and North America, and shipment timing shifts, the company anticipates mid-single-digit core revenue growth for the segment in 2026. Danaher shares have outperformed the industry, but its valuation is higher than peers.
Crane NXT Appoints Jason Lund President of Crane Payment Innovations Unit
Crane NXT has appointed Jason Lund as President of Crane Payment Innovations (CPI) and group president of its Detection and Traceability Technologies (DTT) segment. Lund brings over two decades of industrial technology experience from companies like Novanta, Vontier, Fortive, and Danaher. This appointment follows Crane NXT's strong second-quarter performance, with net income of $35.4 million and a 22% increase in sales to $493.2 million.
Danaher president & CEO Rainer Blair sells $12.7 million in company stock
Rainer Blair, President and CEO of Danaher Corp, sold 58,255 shares of company stock for approximately $12.7 million on August 21, 2026, held indirectly by a trust. This comes as Danaher reported strong Q2 2026 financial results but faces investor concerns regarding bioprocessing guidance. Julie Sawyer Montgomery is set to succeed Blair as President and CEO on October 1, 2026, and analysts have adjusted price targets due to bioproduction timing issues.
Danaher CEO Rainer Blair Executes Sale of 58,255 Trust Shares in August 2026
Danaher CEO Rainer Blair sold 58,255 shares of common stock, held indirectly through a trust, on August 21, 2026. The sales were executed in three tranches at weighted average prices ranging from $217.7711 to $219.3492. After these transactions, the trust's holdings were reduced to zero, while Blair retained 37,988 directly held shares.
Danaher president & CEO Rainer Blair sells $12.7 million in company stock
Danaher President and CEO Rainer Blair sold 58,255 shares of company stock for approximately $12.7 million on August 21, 2026, held indirectly by a trust. This comes as Danaher reported strong Q2 2026 financial results exceeding expectations, though concerns remain regarding bioprocessing guidance and shifts. Analyst price targets have been adjusted, and Julie Sawyer Montgomery is set to succeed Blair as President and CEO on October 1, 2026.
Danaher president & CEO Rainer Blair sells $12.7 million in company stock
Rainer Blair, President and CEO of Danaher Corp, sold 58,255 shares of company stock worth approximately $12.7 million on August 21, 2026. These transactions, detailed in an SEC filing, involved multiple sales at prices ranging from $217.21 to $219.945 per share. Following the sale, Blair's direct beneficial ownership in Danaher is 37,988 shares.
Danaher (NYSE: DHR) CEO sells stock without 10b5-1 plan
Danaher (NYSE: DHR) President & CEO Blair Rainer sold 58,255 shares of common stock through a trust on August 21, 2026, for a total value of approximately $12.74 million. These transactions were conducted in multiple open-market sales with weighted average prices ranging from $217.21 to $219.945 per share. Notably, the sales were not affirmed as being made pursuant to a Rule 10b5-1 trading plan.
Crane NXT names Jason Lund as new President of payments arm CPI
Crane NXT has appointed Jason Lund as President of its currency and payments arm, Crane Payment Innovations (CPI), and Group President of its Detection and Traceability Technologies Segment (DTT). Lund, formerly of Novanta, brings two decades of experience in industrial technology and manufacturing, with a focus on growth, operational excellence, and customer innovation. Crane NXT's CEO, Aaron W Saak, expressed confidence that Lund's leadership will enhance value for customers and shareholders.
Danaher stock rises on $6.26 billion quarter and $219.42 open
Danaher stock saw a rise after its July 20 earnings report, which detailed $1.94 per share and $6.26 billion in revenue, exceeding analyst estimates. The shares opened at $219.42 on August 24, 2026, with a market capitalization of $154.25 billion. Analysts maintain a "Moderate Buy" rating with an average target price of $228.91, reflecting the company's strong profitability in diagnostics and life sciences tools.
Danaher Corp. stock underperforms Monday when compared to competitors
Danaher Corp. (DHR) shares fell by 1.71% on Monday, closing at $215.11, despite a mixed trading session where the Dow Jones Industrial Average rose. This decline ended a three-day winning streak for the company's stock. The S&P 500 Index also experienced a slight dip.
Cytek Owes Beckman Coulter $56 Million at Patent Jury Trial (2)
A federal jury in Delaware has ordered Cytek Biosciences Inc. to pay Beckman Coulter Inc. $56.1 million for infringing on a patent related to tools for analyzing individual cells. The verdict includes $20 million in lost profits and $36.11 million in royalties for Cytek's infringing sales of flow cytometers. The patent in question is Beckman Coulter’s US Patent No. 10,330,582, covering a flow cytometer design, which Cytek's Aurora flow cytometers were found to infringe.
Qiagen names Jonathan Pratt as CEO amid takeover talks
Qiagen N.V. announced that Jonathan M. Pratt will become CEO on September 1, 2026, amidst ongoing discussions with potential buyers. Pratt brings over 25 years of experience in life sciences and laboratory technologies, having previously led Filtration Group and held senior roles at Waters Corporation and Beckman Coulter Life Sciences. The appointment follows a comprehensive search, with Pratt succeeding Thierry Bernard while the company continues to evaluate takeover opportunities, including interest from EQT AB and KKR & Co.
QIAGEN Appoints Jonathan M. Pratt as Chief Executive Officer
QIAGEN N.V. announced the appointment of Jonathan M. Pratt as its new Chief Executive Officer, effective September 1, 2026. Pratt brings over 25 years of international leadership experience in life sciences and laboratory technologies, having previously led Filtration Group and held senior roles at Waters Corporation and Beckman Coulter Life Sciences. Thierry Bernard will step down but support the transition, while QIAGEN reaffirms its outlook for Q3 and full-year 2026 and continues its strategic review.
Crane NXT Names Jason Lund to Lead CPI and DTT Segment
Crane NXT has appointed Jason Lund as president of Crane Payment Innovations (CPI) and group president of its Detection and Traceability Technologies (DTT) segment. In this dual role, Lund will be responsible for accelerating growth, improving operational performance, and advancing customer-focused product development across both businesses. His extensive experience in industrial technology, manufacturing, and M&A integration is expected to be crucial for Crane NXT's strategic expansion in authentication, detection, and traceability markets.
After leading a global robotics and automation business, Jason Lund joins Crane NXT
Crane NXT (NYSE: CXT) has appointed Jason Lund as President of Crane Payment Innovations (CPI) and Group President of its Detection and Traceability Technologies (DTT) segment. Lund brings over two decades of industrial technology experience, including leadership of Robotics & Automation at Novanta, and will focus on growth, operational excellence, and customer-centered innovation in his new role. The company expects his leadership to strengthen its ability to deliver value for customers and shareholders.
Pinnacle Holdings LLC Acquires New Holdings in Talos Energy Inc. $TALO
Pinnacle Holdings LLC has acquired 123,880 shares of Talos Energy Inc. (NYSE:TALO) during the second quarter, valued at approximately $1.6 million. This purchase represents about 0.07% ownership in the company, which is largely held by institutional investors (89.35%). Talos Energy recently reported strong quarterly earnings, surpassing analyst estimates, and maintains a "Moderate Buy" consensus rating from analysts.
Danaher vs. Intuitive Surgical: Is Recovery or Innovation the Better Long-Term Bet?
This article compares Danaher (DHR) and Intuitive Surgical (ISRG) as investment opportunities, highlighting their differing growth paths. Danaher is positioned for a recovery in life sciences spending, while Intuitive Surgical continues to grow through its dominant robotic surgery platform. The piece explores the bull and bear cases for both companies, concluding that the choice depends on an investor's conviction in either cyclical recovery or structural innovation.
Danaher vs. Intuitive Surgical: Is Recovery or Innovation the Better Long-Term Bet?
This article compares Danaher (DHR) and Intuitive Surgical (ISRG) as investment opportunities, highlighting their different growth drivers. Danaher is positioned as a recovery play in life sciences, while Intuitive Surgical represents structural growth through robotic surgery. The author discusses the bull and bear cases for both companies, concluding that the choice depends on whether investors prioritize a broad cyclical recovery or a business with a strong competitive moat and consistent earnings visibility.
Cytek Hit With $56M Verdict For Infringing Cell-Sorting Patent
A Delaware federal jury has awarded Beckman Coulter approximately $56 million in damages after finding that Cytek Biosciences infringed one of its patents related to cell-sorting technology. The patent covers a technology used for quickly analyzing single cells. The verdict was reached on Friday, August 21, 2026.
Does Avantor (AVTR) Analysts’ Upgrades Hint at Durable Fundamental Strength or Short‑Term Optimism?
Avantor (AVTR) recently received an upgrade to Rank #2 (Buy) from Zacks, accompanied by upward revisions to its full-year earnings estimates and improved analyst sentiment. Despite current margin and leverage pressures, analysts are showing increased optimism due to Avantor's strong year-to-date performance compared to the broader Medical sector. However, recent Q2 2026 results showed flat sales and a decline in net income, highlighting that the challenge for Avantor remains converting modest top-line growth into stronger earnings to sustain this positive outlook.
AbCellera Biologics Inc (ABCL) Stock Price, Quote, News & History
This article provides a comprehensive overview of AbCellera Biologics Inc. (ABCL) stock, including its current price, key statistics, recent news, financial data, and analyst forecasts. It highlights the company's performance, particularly mentioning positive Phase 2 results for ABCL635, a menopause drug, and a collaboration with Jazz Pharmaceuticals for cancer therapies. The article also lists competitors and addresses frequently asked questions about buying ABCL stock, dividends, and earnings.
Danaher (NYSE: DHR) holder Blair plans $12.7M stock sale
Rainer M. Blair, a holder of Danaher (NYSE: DHR) common stock, plans to sell 58,255 shares valued at approximately $12.7 million under SEC Rule 144. The shares were acquired as compensation through restricted stock units (RSUs) between 2020 and 2025, and the sale is expected to occur around August 21, 2026, with Goldman Sachs & Co. LLC acting as the broker. This filing indicates 702,986,054 Danaher common shares outstanding, offering transparency regarding insider stock movements.
Danaher Corp. stock outperforms competitors on strong trading day
Danaher Corp. (DHR) shares rose 1.36% to $218.85 on Friday, outperforming the broader stock market, which also saw gains with the S&P 500 Index and Dow Jones Industrial Average rising. This marks the third consecutive day of gains for the company's stock.
Vontier (VNT) Beat And Raised Guidance, Is The 12% Undervaluation Still Compelling?
Vontier (VNT) recently surpassed analyst expectations for earnings and revenue, and also increased its full-year EPS guidance. Despite this positive news, the stock's price has seen a slight decline since the report, although recent momentum shows improvement from a longer-term downtrend. Simply Wall St's analysis indicates Vontier is 12.3% undervalued with a fair value of $37.42 per share, but notes potential concerns regarding sluggish core revenue growth and the evolving electric vehicle market impacting its retail fueling business.
